Examples of using Arbs in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Check the ARBs.
ARBs can sometimes have fewer side effects in patients than ACE inhibitors.
Dual blockade of the RAAS with aliskiren, ARBs or ACEIs.
Infants whose mothers have taken ARBs should be closely observed for hypotension see section 4.3.
This effect is also seen with other medicinal products acting on the RAAS,such as ACEIs and ARBs.
Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren.
This effect is also seen with other agents acting on the renin- angiotensin system,such as ACEIs and ARBs.
The concomitant use of aliskiren and ACEIs or ARBs is contraindicated in patients with renal impairment GFR< 60 ml/min/1.73 m2.
It has demonstrated superior efficacy in lowering blood pressure over previous ARBs in clinical trials.
In fastened state, the ARBS displays all the characteristics of a standard ELR retractor and can also be used optionally for ELR and ALR.
Patients will receive finerenone or placebo on top of current standard of care,which includes RAS-blocking therapy such as ACE inhibitors or ARBs.
When pregnancy is diagnosed, treatment with ARBs should be stopped immediately and, if appropriate, alternative therapy should be started.
In post-marketing experience, cases of angioedema or angioedema-like reactions have been reported whenaliskiren was co-administered with ACEIs and/or ARBs.
What they do Angiotensin II receptor blockers(ARBs) block the actions of angiotensin II, a hormone naturally produced by your kidneys.
In post-marketing experience, angioedema or angioedema-like reactions have been reported whenaliskiren was co-administered with ACEIs and/or ARBs see section 4.8.
The concomitant use of aliskiren and ACEIs or ARBs is contraindicated in patients with diabetes mellitus or renal impairment(GFR< 60 ml/min/1.73 m2) see section 4.3, 4.5 and 4.8.
In a post-authorisation observational study,the co-administration of aliskiren with ACEIs or ARBs has been associated with an increased risk of angioedema.
The combination of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment(GFR< 60 ml/min/1.73 m2) and is not recommended in other patients see sections 4.3, 4.4 and 5.1.
A number of these patients had a history of angioedema or symptoms suggestive of angioedema which in some cases was associated with the administration of other medicinal products known to cause angioedema,including RAAS blockers ACEIs or ARBs.
Clinical trial data has shown that dualblockade of the RAAS through the combined use of ACEIs, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, stroke, hyperkalaemia and decreased renal function(including acute renal failure) compared to the use of a single RAAS-acting agent see sections 4.3, 4.4 and 5.1.
A number of these patients had a history of angioedema or symptoms suggestive of angioedema which in some cases was associated with the administration of other medicines known to cause angioedema,including RAAS blockers ACE inhibitors or ARBs.